RECODE · 연구동향생성일 2026-10-31

연구동향

기준 논문: Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer's disease

Int J Geriatr Psychiatry 31(7):731-739 · 2016 · PMID 26553313

검색 방법

이 논문의 제목과 주제어를 바탕으로 이 논문이 속한 연구 분야를 묻는 질문을 만들어 ReviewFast에 넣어 2026-10-31에 검색했습니다. ReviewFast가 PubMed를 검색하고, AI 모델(Jev)이 제목과 초록을 읽어 질문과의 관련도를 매긴 뒤 주제별로 묶었습니다.

150편 검색→145편 판독→42편 선별 (관련도 0.5 이상)

질문과 PubMed 검색식 보기질문: Selective serotonin reuptake inhibitors such as escitalopram for slowing progression of Alzheimer disease (("selective serotonin reuptake inhibitor*"[tiab] OR SSRI*[tiab] OR escitalopram[tiab] OR fluoxetine[tiab] OR sertraline[tiab] OR citalopram[tiab] OR paroxetine[tiab]) AND ("Alzheimer disease"[tiab] OR "Alzheimer's disease"[tiab] OR "Alzheimer disease"[MeSH Terms] OR "Alzheimer*"[tiab]) AND (progression[tiab] OR "disease progression"[tiab] OR "disease modification"[tiab] OR slow*[tiab] OR neuroprotect*[tiab] OR "cognitive decline"[tiab] OR "disease-modifying"[tiab]))

출판 연도

2005: 1편120052006: 1편12007: 1편12009: 1편12010: 1편120102011: 1편12012: 1편12013: 1편12014: 1편120152016: 3편32017: 3편32018: 3편32019: 2편22020: 2편220202021: 5편52022: 2편22023: 3편32024: 5편52025: 4편42026: 1편12026

선별된 42편의 출판 연도. 검색일(2026-10-31) 기준이며, 그 이후 논문은 들어 있지 않습니다.

주제별 논문

주제 이름은 ReviewFast가 초록의 단어로 자동으로 붙인 것입니다. 왼쪽 숫자는 관련도(0–1)입니다. RECODE 는 우리 연구팀 논문입니다.

01abeta · fluoxetine18편

  1. 0.92

    An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic AD mice

    Sheline YI, West T, Yarasheski K et al. · Science translational medicine · 2014

  2. 0.90

    Fluoxetine delays the cognitive function decline and synaptic changes in a transgenic mouse model of early Alzheimer's disease

    Zhou CN, Chao FL, Zhang Y et al. · The Journal of comparative neurology · 2019

  3. 0.89

    Established amyloid-beta pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine

    Severino M, Sivasaravanaparan M, Olesen LO et al. · Alzheimer's & dementia (New York, N. Y.) · 2018

  4. 0.87

    Long-term Ameliorative Effects of the Antidepressant Fluoxetine Exposure on Cognitive Deficits in 3 x TgAD Mice

    Jin L, Gao LF, Sun DS et al. · Molecular neurobiology · 2017

  5. 0.86

    Fluoxetine and Vortioxetine Reverse Depressive-Like Phenotype and Memory Deficits Induced by Abeta(1-42) Oligomers in Mice: A Key Role of Transforming Growth Factor-beta1

    Torrisi SA, Geraci F, Tropea MR et al. · Frontiers in pharmacology · 2019

  6. 0.84

    Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimer's disease

    Reddy AP, Sawant N, Morton H et al. · Human molecular genetics · 2021

  7. 0.84

    Fluoxetine attenuates the impairment of spatial learning ability and prevents neuron loss in middle-aged APPswe/PSEN1dE9 double transgenic Alzheimer's disease mice

    Ma J, Gao Y, Jiang L et al. · Oncotarget · 2017

  8. 0.82

    Fluoxetine Prevents Abeta(1-42)-Induced Toxicity via a Paracrine Signaling Mediated by Transforming-Growth-Factor-beta1

    Caraci F, Tascedda F, Merlo S et al. · Frontiers in pharmacology · 2016

  9. 0.82

    Protective effects of antidepressant citalopram against abnormal APP processing and amyloid beta-induced mitochondrial dynamics, biogenesis, mitophagy and synaptic toxicities in Alzheimer's disease

    Reddy AP, Yin X, Sawant N et al. · Human molecular genetics · 2021

  10. 0.81

    Neuroprotective Effects of Fluoxetine on Molecular Markers of Circadian Rhythm, Cognitive Deficits, Oxidative Damage, and Biomarkers of Alzheimer's Disease-Like Pathology Induced under Chronic Constant Light Regime in Wistar Rats

    Sharma A, Mohammad A, Saini AK et al. · ACS chemical neuroscience · 2021

  11. 0.80

    Paroxetine ameliorates prodromal emotional dysfunction and late-onset memory deficit in Alzheimer's disease mice

    Ai PH, Chen S, Liu XD et al. · Translational neurodegeneration · 2020

  12. 0.80

    Fluoxetine ameliorates Alzheimer's disease progression and prevents the exacerbation of cardiovascular dysfunction of socially isolated depressed rats through activation of Nrf2/HO-1 and hindering TLR4/NLRP3 inflammasome signaling pathway

    Abu-Elfotuh K, Al-Najjar AH, Mohammed AA et al. · International immunopharmacology · 2022

  13. 0.78

    Antioxidant Activity of Fluoxetine and Vortioxetine in a Non-Transgenic Animal Model of Alzheimer's Disease

    Caruso G, Grasso M, Fidilio A et al. · Frontiers in pharmacology · 2021

  14. 0.78

    Attenuative Effects of Fluoxetine and Triticum aestivum against Aluminum-Induced Alzheimer's Disease in Rats: The Possible Consequences on Hepatotoxicity and Nephrotoxicity

    Abu-Elfotuh K, Ragab GM, Salahuddin A et al. · Molecules (Basel, Switzerland) · 2021

  15. 0.73

    Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans

    Keowkase R, Aboukhatwa M, Luo Y · Neuropharmacology · 2010

  16. 0.70

    Midbrain degeneration triggers astrocyte reactivity and tau pathology in experimental Alzheimer's Disease

    La Barbera L, Krashia P, Loffredo G et al. · Molecular neurodegeneration · 2025

  17. 0.64

    Fluoxetine administration during adolescence attenuates cognitive and synaptic deficits in adult 3xTgAD mice

    Sun DS, Gao LF, Jin L et al. · Neuropharmacology · 2017

  18. 0.64

    Comparison of Protective Effects of Antidepressants Mediated by Serotonin Receptor in Abeta-Oligomer-Induced Neurotoxicity

    Yamamoto K, Tsuji M, Oguchi T et al. · Biomedicines · 2024

02cognitive · change15편

  1. 0.95

    Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer's disease 이 논문

    Choe YM, Kim KW, Jhoo JH et al. · International journal of geriatric psychiatry · 2016

  2. 0.92

    Effect of SSRIs on clinical progression in amnestic mild cognitive impairment stratified by Alzheimer's disease pathology

    Li Y, Liu W, Wang X et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

  3. 0.91

    Relationship Between SSRI Exposure During Later Life and Clinical and Neuropathological Correlates of Dementia

    Shaw JS, Bray MJC, Harrington CK et al. · The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2026

  4. 0.91

    Comparing the effects of four common drug classes on the progression of mild cognitive impairment to dementia using electronic health records

    Xu J, Wang F, Zang C et al. · Scientific reports · 2023

  5. 0.91

    Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms

    Brendel M, Sauerbeck J, Greven S et al. · Journal of Alzheimer's disease : JAD · 2018

  6. 0.91

    Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer's Dementia in Individuals With Previous Depression

    Bartels C, Wagner M, Wolfsgruber S et al. · The American journal of psychiatry · 2018

  7. 0.89

    SSRIs reduce plasma tau and restore dorsal raphe metabolism in Alzheimer's disease

    Terstege DJ, Jabeen S, Galea LAM et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

  8. 0.88

    Selective serotonin reuptake inhibitor use, age-related neuropathology and cognition in late-life

    Sood A, Wilson RS, Yu L et al. · Psychiatry research · 2023

  9. 0.81

    Long-term effects of antidepressants on cognition in patients with Alzheimer's disease

    Caballero J, Hitchcock M, Beversdorf D et al. · Journal of clinical pharmacy and therapeutics · 2006

  10. 0.80

    Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial

    Mowla A, Mosavinasab M, Pani A · Journal of clinical psychopharmacology · 2007

  11. 0.79

    Conversion to Mild Cognitive Impairment and Alzheimer's Disease Dementia Related to Apathy, APOE Genotype and Antidepressant Use

    Malik R, Martinez MR, So I et al. · Journal of geriatric psychiatry and neurology · 2025

  12. 0.78

    R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation

    Ho T, Pollock BG, Mulsant BH et al. · British journal of clinical pharmacology · 2016

  13. 0.65

    Integrated treatment approach improves cognitive function in demented and clinically depressed patients

    Bragin V, Chemodanova M, Dzhafarova N et al. · American journal of Alzheimer's disease and other dementias · 2005

  14. 0.65

    Impact of Different Diagnostic Measures on Drug Class Association with Dementia Progression Risk: A Longitudinal Prospective Cohort Study

    Kaur DP, Bucholc M, Finn DP et al. · Journal of Alzheimer's disease : JAD · 2024

  15. 0.62

    A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints

    Lavretsky H, Laird KT, Krause-Sorio B et al. · The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2020

03neurodegenerative · activity5편

  1. 0.85

    The effect of citalopram treatment on amyloid-beta precursor protein processing and oxidative stress in human hNSC-derived neurons

    Elsworthy RJ, Crowe JA, King MC et al. · Translational psychiatry · 2022

  2. 0.60

    Low TGF-beta1 plasma levels are associated with cognitive decline in Down syndrome

    Grasso M, Fidilio A, L'Episcopo F et al. · Frontiers in pharmacology · 2024

  3. 0.56

    Evaluation of pyrimidine/pyrrolidine-sertraline based hybrids as multitarget anti-Alzheimer agents: In-vitro, in-vivo, and computational studies

    Javed MA, Jan MS, Shbeer AM et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023

  4. 0.56

    Inhibitory Actions of Antidepressants, Hypnotics, and Anxiolytics on Recombinant Human Acetylcholinesterase Activity

    Obara K, Mori H, Ihara S et al. · Biological & pharmaceutical bulletin · 2024

  5. 0.53

    iPSC-derived hindbrain organoids to evaluate escitalopram oxalate treatment responses targeting neuropsychiatric symptoms in Alzheimer's disease

    Zivko C, Sagar R, Xydia A et al. · Molecular psychiatry · 2024

04trials · review3편

  1. 0.86

    The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease

    Rosenberg PB, Mielke MM, Han D et al. · International journal of geriatric psychiatry · 2012

  2. 0.83

    Antidepressants and dementia

    Kessing LV, Sondergard L, Forman JL et al. · Journal of affective disorders · 2009

  3. 0.78

    Do continued antidepressants protect against dementia in patients with severe depressive disorder?

    Kessing LV, Forman JL, Andersen PK · International clinical psychopharmacology · 2011

05parkinson · antidepressants1편

  1. 0.73

    Effects of corticosterone and amyloid-beta on proteins essential for synaptic function: implications for depression and Alzheimer's disease

    Wuwongse S, Cheng SSY, Wong GTH et al. · Biochimica et biophysica acta · 2013